Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Mar 4;7(3):e241155.
doi: 10.1001/jamanetworkopen.2024.1155.

Effect of Ergocalciferol on β-Cell Function in New-Onset Type 1 Diabetes: A Secondary Analysis of a Randomized Clinical Trial

Benjamin Udoka Nwosu  1   2 , Sadichchha Parajuli  2   3 , Rohit B Sharma  4 , Austin F Lee  5
Affiliations
Randomized Controlled Trial

Effect of Ergocalciferol on β-Cell Function in New-Onset Type 1 Diabetes: A Secondary Analysis of a Randomized Clinical Trial

Benjamin Udoka Nwosu et al. JAMA Netw Open. .
No abstract available

Plain language summary

This secondary analysis of a randomized clinical trial evaluates the effectiveness of ergocalciferol vs placebo in youths with newly diagnosed type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Fasting Proinsulin, Fasting C-Peptide, and Corresponding Proinsulin to C-Peptide Ratios (PI:Cs)
A and B, Observed (A) and model-predicted (B) PI:Cs. Trends were generated from a repeated-measures generalized linear model of fasting PI:Cs. The total number of repeated-measures observations was 149 from 36 participants (18 per group). Three observed values were greater than 0.2; these were considered extreme outliers and were removed (in A). The remaining observations ranged from 0.005 to 0.087. The error distribution was normal, the link function was logarithmic, the repeated-measures correlation was unstructured, and the difference in trends between the 2 groups was significant (P = .01). C, Overall analysis of the trends showed that ergocalciferol significantly slowed the decline in percentage AUC C-peptide from baseline compared with placebo (P = .03).
See this image and copyright information in PMC

References

    1. Nwosu BU, Parajuli S, Jasmin G, et al. Ergocalciferol in new-onset type 1 diabetes: a randomized controlled trial. J Endocr Soc. 2021;6(1):bvab179. doi: 10.1210/jendso/bvab179 - DOI - PMC - PubMed
    1. Yu MG, Keenan HA, Shah HS, et al. Residual β cell function and monogenic variants in long-duration type 1 diabetes patients. J Clin Invest. 2019;129(8):3252-3263. doi: 10.1172/JCI127397 - DOI - PMC - PubMed
    1. Nwosu BU, Parajuli S, Jasmin G, et al. Investigational study protocol. 2021. Accessed January 27, 2024. https://repository.escholarship.umassmed.edu/handle/20.500.14038/28276
    1. Forlenza GP, McVean J, Beck RW, et al. ; CLVer Study Group . Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA. 2023;329(12):990-999. doi: 10.1001/jama.2023.2064 - DOI - PMC - PubMed
    1. Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. Diabetes Care. 1995;18(2):245-250. doi: 10.2337/diacare.18.2.245 - DOI - PubMed

Publication types

Substances